PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)

被引：0
|
作者：
Chiney, M. S. [1 ]
Polepally, A. R. [1 ]
Nader, A. M. [1 ]
Dufek, M. B. [1 ]
Klein, C. E. [1 ]
Ng, J. W. [1 ]
Shebley, M. [1 ]
机构：
[1] Abbvie, N Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-022
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [21] Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites
    Zhang, Tao
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 : 216 - 229
  • [22] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING IN PREDICTING DRUG-DRUG INTERACTIONS FOR TELMISARTAN IN HUMANS
    Kim, Jeong Ho
    Heo, Hyunjin
    Min, Jee Sun
    Kim, Doyun
    Bae, Soo Hyeon
    Bae, Soo Kyung
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S109 - S110
  • [23] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ATORVASTATIN AND RELATED SPECIES AND PREDICTION OF DRUG-DRUG INTERACTIONS IN HUMANS.
    Morse, B. L.
    Alberts, J. J.
    Kolur, A.
    Posada, M. M.
    Tham, L.
    Loghin, C.
    Hall, S. D.
    Dickinson, G. L.
    Hillgren, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S63 - S64
  • [24] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin and Prediction of Transporter-Mediated Drug-Drug Interactions Involving Gemfibrozil
    Macwan, J. S.
    Lukacova, V.
    Fraczkiewicz, G.
    Bolger, M. B.
    Akhlaghi, F.
    Woltosz, W. S.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S39 - S39
  • [25] APPLICATION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR PREDICTION OF THE DRUG-DRUG INTERACTION (DDI) BETWEEN LORAZEPAM AND PROBENECID
    Neuhoff, Sibylle
    Musther, Helen
    Rowland-Yeo, Karen
    DRUG METABOLISM REVIEWS, 2015, 47 : 121 - 121
  • [26] Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
    Zhou, D.
    Bui, K.
    Sostek, M.
    Al-Huniti, N.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (05): : 250 - 257
  • [27] Determination of Vatiquinone Drug-Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
    Lee, Lucy
    Okudaira, Noriko
    Murase, Katsuyuki
    Kong, Ronald
    Jones, Hannah M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (02): : 160 - 169
  • [28] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions
    Ruben de Kanter
    Patricia N. Sidharta
    Stéphane Delahaye
    Carmela Gnerre
    Jerome Segrestaa
    Stephan Buchmann
    Christopher Kohl
    Alexander Treiber
    Clinical Pharmacokinetics, 2016, 55 : 369 - 380
  • [29] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE DRUG-DRUG INTERACTION (DDI) RISK OF ALECTINIB.
    Cleary, Y.
    Gertz, M.
    Morcos, P. N.
    Youdim, K.
    Fowler, S.
    Yu, L.
    Sekiguchi, N.
    Takanashi, K.
    Kaneko, A.
    Phipps, A.
    Parrott, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S40 - S40
  • [30] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO EVALUATE POTENTIAL CYP-MEDIATED DRUG-DRUG INTERACTIONS (DDI) WITH SELUMETINIB.
    Zhou, L.
    Cohen-Rabbie, S.
    Vishwanathan, K.
    Schalkwijk, S.
    Tomkinson, H.
    Al-Huniti, N.
    Zhou, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S92 - S93
12345